eMedicine Specialties > Pediatrics: General Medicine > Oncology

Rhabdomyosarcoma

Timothy P Cripe, MD, PhD, Professor of Pediatric Hematology/Oncology, University of Cincinnati; Director, Translational Research Trials Office, Department of Pediatrics, Cincinnati Children's Hospital Medical Center

Updated: Dec 2, 2008

Introduction

Background

Rhabdomyosarcoma (RMS)  is the most common soft tissue sarcoma in children.¹ The name is derived from the Greek words rhabdo, which means rod shape, and myo, which means muscle. Although Weber first described rhabdomyosarcoma in 1854, a clear histologic definition was not available until 1946, when Stout recognized the distinct morphology of rhabdomyoblasts.² Stout described rhabdomyoblasts as appearing in round, strap, racquet, and spider forms. As its name suggests, the tumor is believed to arise from a primitive muscle cells. Rhabdomyoblasts sometimes have discernible muscle striations that are visible on specimens under light microscopy, although electron microscopy may be needed to detect subcellular elements. Cells are usually positive for intermediate filaments and other proteins typical of differentiated muscle cells, such as desmin, vimentin, myoglobin, actin, and transcription factor myoD.

Several distinct histologic groups have prognostic significance, including embryonal rhabdomyosarcoma (ERMS), which occurs in 55% of patients; the botryoid variant of ERMS, which occurs in 5% of patients; alveolar rhabdomyosarcoma (ARMS), which occurs in 20% of patients; and undifferentiated sarcoma (UDS), which occurs in 20% of patients.³

Treatment responses and prognoses widely vary depending on location and histology. Studies tumor biology and treatment in patients with rhabdomyosarcoma at a single institution, or even at regional centers, are not possible because of the variable nature and uncommon occurrence of the tumors. Therefore, most advances in knowledge and treatment have resulted from cooperative group studies.

Pathophysiology

Although the tumor is believed to arise from primitive muscle cells, tumors can occur anywhere in the body except bone. The most common sites are the head and neck (28%), extremities (24%), and genitourinary (GU) tract (18%). Other notable sites include the trunk (11%), orbit (7%), and retroperitoneum (6%). Rhabdomyosarcoma occurs at other sites in less than 3% of patients. The botryoid variant of ERMS arises in mucosal cavities, such as the bladder, vagina, nasopharynx, and middle ear. Lesions in the extremities are most likely to have an alveolar type of histology. Metastases are found predominantly in the lungs, bone marrow, bones, lymph nodes, breasts, and brain.

As with most tumors of childhood, the cause of rhabdomyosarcoma is unknown. The alveolar variant is so named because of the thin criss-crossing fibrous bands that appear as spaces between cellular regions of the tumor (reminiscent of lung alveoli). This variant is usually associated with 1 of 2 chromosomal translocations, namely, t(2;13) or t(1;13). These result in the fusion of the DNA-binding domain of the neuromuscular developmental transcription factors, encoded by PAX3 on chromosome 2 or PAX7 on chromosome 1.⁴ The transcriptional activation domain of a relatively ubiquitous transcription factor, FKHR (or FOXO1a), is encoded on chromosome 13.

The resulting hybrid molecule is a potent transcription activator. It is believed to contribute to the cancerous phenotype by abnormally activating or repressing other genes. The embryonal subtype usually has a loss of heterozygosity at band 11p15.5; this observation suggests the presence of a tumor suppressor gene. Other molecular aberrations that may provide clues to the origin of the tumor and that may be useful for future treatment strategies include TP53 mutations (which occurs in approximately one half of patients), an elevated N-myc level (in 10% of patients with ARMS), and point mutations in N-ras and K-ras oncogenes (usually embryonal). In addition, levels of insulinlike growth factor-2 may be elevated, suggesting pathways involving autocrine and paracrine growth factors.⁵

Frequency

United States

The incidence is 6 cases per 1,000,000 population per year (approximately 250 cases) in children and adolescents younger than 15 years.

International

No notable geographic predilection is reported.

Mortality/Morbidity

In patients with localized disease, overall 5-year survival rates have improved to more than 80% with the combined use of surgery, radiation therapy, and chemotherapy.⁶ However, in patients with metastatic disease, little progress has been made in survival rates, with a 5-year event-free survival rate less than 30%. Those patients with metastatic disease without other high-risk factors, including unfavorable site, more than 3 sites, bone marrow involvement, and age younger than 1 year or older than 10 years, have a better prognosis (50% 3-y event-free survival) than those with 3-4 of these factors (12% and 5% 3-y event-free survival, respectively).⁷ The use of high-dose myeloablative therapy with autologous stem-cell rescue has not improved outcomes for these patients.

In an analysis of data collected by the Surveillance, Epidemiology, and End Results (SEER) program, mortality was highly related to age, site, and histology.⁸ The 5-year survival was highest in children aged 1-4 years (77%) and was worst in infants and adolescents (47% and 48%, respectively). Orbital and GU sites were the most favorable (86% and 80%, respectively). Unfavorable sites included tumors of the extremities (50%), retroperitoneum (52%), and trunk (52%). Embryonal histology was best (67%) compared with alveolar histology (49%). Most patients with local recurrence are curable with salvage therapy, particularly if the recurrence is after initial therapy has been completed.

Race

No racial predilection is obvious.

Sex

Overall, the male-to-female ratio is 1.2-1.4:1. Differences are observed according to the site of primary disease.

• GU tract: The male-to-female ratio is 3.3:1 in patients with bladder or prostate involvement and 2.1:1 in rhabdomyosarcoma of the GU tract without bladder or prostate involvement.
• Extremity: The male-to-female ratio is 0.79:1.
• Orbit: The male-to-female ratio is 0.88:1.

Age

Approximately 87% of patients are younger than 15 years, and 13% of patients are aged 15-21 years. Rhabdomyosarcoma rarely affects adults. Age-related differences are observed for the different sites of primary disease. Two age peaks tend to be associated with different locations. Patients aged 2-6 years tend to have head and neck or GU tract primary tumors, whereas adolescents aged 14-18 y tend to have primary tumors in extremity, truncal, or paratesticular locations.

• GU tract: In patients with bladder or prostate involvement, 73% are younger than 5 years. In patients with rhabdomyosarcoma of the GU tract without bladder or prostate involvement, 27% are older than 15 years.
• Orbit: About 42% of patients with orbital rhabdomyosarcoma are aged 5-9 years.

Clinical

History

Rhabdomyosarcoma (RMS) usually manifests as an expanding mass; symptoms depend on the location of the tumor. Pain may be present. If metastatic disease is present, symptoms of bone pain, respiratory difficulty (secondary to lung nodules or to pleural effusion), anemia, thrombocytopenia, and neutropenia may be present. Disseminated rhabdomyoblasts in the bone marrow may mimic leukemia, both in symptoms and light microscopic findings.

Typical presentations by the location of nonmetastatic disease are as follows:

• Orbit - Proptosis or dysconjugate gaze
• Paratesticular - Painless scrotal mass
• Prostate - Bladder or bowel difficulties
• Uterus, cervix, bladder - Menorrhagia or metrorrhagia
• Vagina - Protruding polypoid mass (botryoid, meaning a grapelike cluster)
• Extremity - Painless mass
• Parameningeal (ear, mastoid, nasal cavity, paranasal sinuses, infratemporal fossa, pterygopalatine fossa) - Upper respiratory symptoms or pain

Physical

Physical findings depend on the location of the tumor. Tumors in superficial locations may be palpable and detected relatively early, but those in deep locations (eg, retroperitoneum) may grow large before causing symptoms.

Causes

The cause of rhabdomyosarcoma is unclear. Several genetic syndromes and environmental factors are associated with increased prevalence of rhabdomyosarcoma.

• Genetic syndromes include the following:
  • Neurofibromatosis (4-5% risk of any one of numerous malignancies)
  • Li-Fraumeni syndrome (germline mutation of the tumor suppressor gene TP53)
  • Rubinstein-Taybi syndrome
  • Gorlin basal cell nevus syndrome
  • Beckwith-Wiedemann syndrome
  • Costello syndrome⁹
• A higher prevalence of congenital anomalies are observed in patients who later develop rhabdomyosarcoma with locations as follows:
  • Genitourinary (GU) tract
  • CNS (ie, Arnold-Chiari malformation)
  • GI tract
  • Cardiovascular system
• Environmental factors appear to influence the development of rhabdomyosarcoma, as follows:
  • Parental use of marijuana and cocaine
  • Intrauterine exposure to X-rays
  • Previous exposure to alkylating agents

Differential Diagnoses

Workup

Laboratory Studies

The following studies are indicated in rhabdomyosarcoma:

• CBC count: Anemia may be present because of inflammation, or pancytopenia may be present from bone marrow involvement.
• Liver function tests, including measurement of lactic acid dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and bilirubin levels: Metastatic disease of the liver may affect values of these proteins. Liver function must be assessed before chemotherapy.
• Renal function tests, including measurements of BUN and creatinine levels: Renal function must be assessed before chemotherapy.
• Urinalysis (UA): Hematuria may indicate involvement of the genitourinary (GU) tract.
• Blood electrolyte and chemistry, including evaluation of sodium, potassium, chlorine, carbon dioxide, calcium, phosphorous, and albumin values: Assess for abnormalities before chemotherapy.

Imaging Studies

• Plain radiography: Radiography of the primary site and of the chest is helpful in determining the presence of calcifications and bone involvement of the primary tumor and to search for metastatic lung lesions.
• CT scanning
  • Obtain a chest CT scan to evaluate for metastases to the lungs. Chest CT scanning is best performed before surgery to avoid atelectasis, which can be confused with metastasis.
  • A CT scan of the primary site may also be helpful in evaluating for bone erosion, if present, and to follow up the patient's response to therapy.
  • Obtain a CT scan of the liver in patients with abdominal or pelvic primary tumors to assess for metastatic spread. Ultrasonography is an alternative.
• MRI: MRI improves definition of the mass and its invasion of adjacent organs, especially in orbital, paraspinal, or parameningeal regions. Obtain an MRI of the head if the patient is symptomatic at diagnosis.
• Bone scanning: Search for metastases to the bones.
• Ultrasonography: Obtain sonograms of the liver in patients with abdominal or pelvic tumors. CT scanning is an alternative.
• Echocardiography: Assess cardiac function before chemotherapy.

Procedures

• Biopsy: Open biopsy best enables adequate tissue sampling for diagnosis and molecular studies. Core needle biopsy is an alternative. Depending on the location, definitive surgery can be postponed to allow for neoadjuvant chemotherapy to shrink the tumor.
• Cytogenetics, fluorescent in situ hybridization (FISH)
  • This study helps in determining if the translocations t(1;13) or t(2;13), which are associated with the alveolar subtype, are present.
  • FISH also helps in the differential diagnosis if a translocation characteristic of another tumor type is present.
  • FISH is most sensitive for these translocations and can be helpful in evaluating residual disease.
• Reverse transcriptase–polymerase chain reaction (RT-PCR) testing
  • When cytogenetic testing is unavailable (eg, culture failure) or when its results are uninformative, order a RT-PCR reaction to assess for the characteristic translocations associated with alveolar rhabdomyosarcoma (ARMS) and other small, round blue-cell tumors of childhood.
  • In many centers, the use of RT-PCR to screen for a panel of translocations associated with soft tissue sarcomas is becoming a routine adjunct to morphologic analysis to help ascertain the diagnosis.
• Bone marrow aspiration and biopsy: Assess for metastatic spread to bone marrow.

Histologic Findings

Rhabdomyosarcoma is one of the small, round blue-cell tumors of childhood. Occasionally, these types of tumors can be difficult to differentiate. Rhabdomyosarcoma cells tend to have variable differentiation along the myogenesis pathway and may appear as strap cells or myotubes that sometimes contain muscle cross-striations. Rhabdomyosarcoma cells may demonstrate positive immunohistochemical results for muscle-specific markers, such as myoglobin, actin, and desmin.¹⁰

Cells from the rhabdomyosarcoma subtypes have the following distinctive features:

• Botryoid: The cambium layer is characteristic, containing a condensation of loose tumor cells below an epithelial surface.
• Alveolar: Cells line up along membranes that may be imperceptibly thin or that may be obvious collagen bands resembling the lung alveoli. A tumor should be classified as this type if any portion of it appears to be alveolar.
• Undifferentiated: No evidence of myogenesis differentiation is usually present.

Treatment

Medical Care

Treatment in patients with rhabdomyosarcoma (RMS) involves a combination of surgery, chemotherapy, and radiation therapy. Because the treatment plan is complicated and prolonged and because many medical issues are unique to pediatric oncology, all patients should be referred (at least initially) to a center with personnel who are skilled in caring for children with cancer.

At present, patients are categorized according to their risk, which takes into account the location of the tumor and the histologic and surgical results. Low-risk patients are those who have the best prognosis, whereas intermediate-risk or high-risk patients have an increased of having relapses and incurable disease. To separate the features into meaningful categories, patients are assigned to both a surgicopathologic clinical group (Roman numeral) and a stage (Arabic numeral). All patients with metastatic disease (group IV, stage 4) are considered high risk, except children and adolescents younger than 14 years with embryonal rhabdomyosarcoma (ERMS). In some studies, these patients appear to do better than others, for unknown reasons. Although all patients require chemotherapy, regimens vary depending on the stage and group.

• Surgicopathologic (clinical) group (Groups I-III are for localized disease.) 
  • Group I - Tumor completely removed
  • Group II - Microscopic residual tumor, involved regional nodes, or both
  • Group III - Gross residual tumor
  • Group IV - Distant metastatic disease
• Tumor, nodes, and metastases (TNM) staging system 
  • Tumor - Confined to the site of origin (T1) or extends beyond the site of origin (T2)
  • Node - No regional node involvement (N0), regional node involvement (N1), or nodes unknown (NX)
  • Metastasis - No metastasis (M0), or metastases present at diagnosis (M1)
• RMS staging system 
  • Stage 1 - Orbit, head, and/or neck (not parameningeal) involvement, and involvement of the GU tract (not bladder or prostate)
  • Stage 2 - Other locations, N0 or NX
  • Stage 3 - Other locations, N1 if the tumor is less than 5 cm or N0 or NX if the tumor more than 5 cm
  • Stage 4 - Any site with distant metastases
• Low-risk patients are those with the following embryonal histology: 
  • Stages 1-3 in groups I-II (or III for only orbital involvement)
  • Stage 1 in group III
• Intermediate-risk patients are those with the following embryonal histology:
  • Stages 2-3 in clinical group III (nonorbital involvement)
  • Stage 4 in clinical group IV if patient is younger than 14 years

Surgical Care

Surgical management of rhabdomyosarcoma varies depending on the location of the tumor. If feasible, remove tumors promptly and without unacceptable disfigurement or loss of function. Even if metastatic disease is present, surgical excision of the primary site should be performed, if possible. The surgical result helps determine the clinical grouping to be used for treatment stratification.

Surgical guidelines for the various sites can be found in the protocols of the Children's Oncology Group Soft Tissue Sarcoma Committee (formerly, Intergroup Rhabdomyosarcoma Study Group [IRSG]) and are beyond the scope of this article. However, common principles are noteworthy and described below.

• Primary tumor
  • Because relapses often occur at the site of the original primary tumor, adequate local control is essential.
  • Data from Europe suggest that chemotherapy alone can be effective for achieving adequate local control in some patients who have a complete response of the primary tumor. However, surgery and/or irradiation are needed for local control of residual disease.
  • If possible, complete excision of the lesion should be performed with wide (2-cm) margin of healthy tissue. Wide margins of normal tissue often are impossible to achieve at certain sites, such as the head and neck. If margins are narrow, obtain several biopsy specimens from the surrounding tissue to assess for residual local disease.
  • For tumors that cannot be excised at diagnosis, a second-look procedure may be appropriate after a period of chemotherapy (usually 12 wk).
• Lymph nodes
  • Regional lymph nodes that appear to be clinically or radiographically involved should be sampled to determine the clinical group and the need for later radiation therapy.
  • Radical node dissection is not appropriate.
  • Axillary and femoral node sampling should be performed for lesions in the extremities, even if clinical findings are negative because of the high prevalence of metastatic disease arising from extremity lesions.

Consultations

The care of patients with rhabdomyosarcoma is complicated and extensive and touches all aspects of their lives. Initial evaluation and treatment should be undertaken at a center with a comprehensive program for children with cancer.

• Radiotherapist
  • Most patients with rhabdomyosarcoma require radiotherapy to achieve adequate local control, though radiotherapy is not usually performed until after initial surgical resection and the start of chemotherapy. Exceptions are patients with parameningeal primary tumors, for which initial radiotherapy has been shown to be beneficial.
  • A radiotherapist familiar with the requirements for clinical trials should be consulted at diagnosis for most patients in North America to determine if they have any special needs for treatment planning.
  • In initial studies, new techniques such as intensity-modulated radiotherapy (IMRT) and proton-beam radiotherapy appear to achieve adequate tumor control with reduced exposure to normal tissues.^11,12
• Psychosocial team: The psychosocial team is critical for helping patients and families cope with the stresses associated with the diagnosis and treatment of cancer. The social worker usually plays an intimate role in helping families navigate complicated insurance and financial issues.
• Dentist: A thorough dental evaluation is required to identify potential problems that may arise during chemotherapy.
• Pediatric therapists: Activities and therapy can be critical in helping the patient through the phases of medical therapy.

Diet

No specific dietary recommendations are needed. However, patients may require nasogastric feedings or parenteral nutrition during some phases of chemotherapy. This is especially true for patients with primary tumors in head and neck, who may have severe mucositis after radiation therapy.

Activity

No specific activity limitations are required. The patient's activity is restricted only as the location of the tumor and the adverse effects of treatment dictate.

Medication

Standard therapy for rhabdomyosarcoma (RMS) includes chemotherapy combined with surgical resection, radiotherapy, or both for local control, if necessary. These modalities have not improved survival rates in patients with metastatic disease; however, new agents active against rhabdomyosarcoma are being sought, and agents are being tested in phase I and II clinical trials. Novel therapies in development include oncolytic viruses¹³ and immunotherapies, such as monoclonal antibodies¹⁴ and dendritic-cell vaccines. In addition, evidence suggests that some targeted agents may be active in rhabdomyosarcoma, including proteosome inhibitors,¹⁵ and anti-insulinlike growth factor receptor (IGFR) antibodies.¹⁶ The role of oral maintenance therapy may be useful in controlling metastatic disease but has not been confirmed.¹⁷

Antineoplastics agents

This therapy is aimed at killing tumor cells. Cancer chemotherapy is based on an understanding of how tumor cell grow and of how drugs affect this growth. After cells divide, they enter a period of growth (phase G1), followed by DNA synthesis (phase S). The next phase is a premitotic phase (G2) and, finally, mitotic cell division (phase M) occurs.

The cell-division rate varies for different tumors. Tumors of most common cancers grow slowly compared with normal tissues, and the rate of growth may decrease further in large tumors. This difference allows normal cells to recover from chemotherapy more quickly than malignant cells can and is the rationale behind current cyclic dosing schedules.

Antineoplastic agents interfere with cell reproduction. Some agents are phase specific, whereas others (eg, alkylating agents, anthracyclines, cisplatin) are not. Cellular apoptosis (ie, programmed cell death) is a potential mechanism of many antineoplastic agents. Those listed here are the standard active agents, although others, such as irinotecan, appear useful and are under investigation in current clinical trials.¹⁸

Vincristine (Oncovin)

Inhibits tubulin polymerization, targeting dividing cells. Acts as vesicant.

Dosing

Adult

2 mg IV slow push into central venous catheter or fresh IV line; acts as vesicant

Pediatric

1.5 mg/m² IV q1-3wk; not to exceed 2 mg/dose

Interactions

Acute pulmonary reaction may occur when administered concurrently with mitomycin-C; asparaginase, cytochrome P450 (CYP) 3A4 inhibitors (eg, itraconazole, quinupristin-dalfopristin, sertraline, ritonavir), granulocyte-macrophage colony-stimulating factor (GM-CSF, eg, sargramostim, filgrastim), or nifedipine increase toxicity; CYP3A4 inducers (eg, carbamazepine, phenytoin, phenobarbital, rifampin) may decrease effects

Contraindications

Documented hypersensitivity; intrathecal use; severe neurotoxicity from previous dose; Charcot-Marie-tooth syndrome

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in severe cardiopulmonary disease, hepatic impairment (adjust dose), or preexisting neuromuscular dysfunction; may cause nausea, vomiting, diplopia, neuromyopathy, myelosuppression, alopecia, or constipation

Dactinomycin (Cosmegen, actinomycin D)

Antibiotic derived from Streptomyces bacteria.

Dosing

Adult

0.5 mg/d IV push for 5 d

Pediatric

0.015 mg/kg/d IV push for 5 d or 1.5 mg IV push q3wk

Interactions

May interfere with immune response to live virus vaccine (MMR) and reduce efficacy

Contraindications

Documented hypersensitivity; varicella; herpes zoster; concomitant radiation therapy

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Vesicant (avoid extravasation); may cause nausea, vomiting, diarrhea, stomatitis, myelosuppression, hepatotoxicity, dermatitis, or hyperpigmentation (especially with previous radiation exposure)

Cyclophosphamide (Cytoxan)

Alkylating agent believed to be cytotoxic to dividing cells by cross-linking cellular DNA. Processed in liver to active metabolites. Byproducts (eg, acrolein) accumulate in bladder and cause cystitis.

Dosing

Adult

400 mg/m²/d PO for 5 d or 1-1.5 g/m² IV q3-4wk

Pediatric

1.2-2.2 g/m²/d IV for 1-3 d

Interactions

Allopurinol may increase risk of bleeding or infection and enhance myelosuppressive effects; may potentiate doxorubicin-induced cardiotoxicity; may reduce digoxin serum levels and antimicrobial effects of quinolones; toxicity may increase with chloramphenicol; may increase effect of anticoagulants; coadministration with high doses of phenobarbital may increase leukopenic activity; thiazide diuretics may prolong cyclophosphamide-induced leukopenia; coadministration with succinylcholine may increase neuromuscular blockade by inhibiting cholinesterase activity; may interfere with immune response to live virus vaccine (MMR) and reduce efficacy

Contraindications

Documented hypersensitivity; severely depressed bone marrow function; severe hemorrhagic cystitis

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Regularly examine hematologic profiles (particularly neutrophils and platelets) to monitor for hematopoietic suppression; regularly examine urine for RBCs, which may precede hemorrhagic cystitis; cardiotoxicity occurs with high doses

Etoposide (Toposar, VP16)

Inhibits topoisomerase II and therefore toxic to cells undergoing DNA replication.

Dosing

Adult

50-100 mg/m²/d IV for 5 d
PO dose: 2 times IV dose rounded to nearest 50 mg

Pediatric

100 mg/m²/d IV for 5 d

Interactions

May prolong effects of warfarin and increase methotrexate clearance; cyclosporine and etoposide have additive effects in cytotoxicity of tumor cells; may interfere with immune response to live virus vaccine (MMR) and reduce efficacy

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

May cause nausea, vomiting, myelosuppression, or alopecia; adjust dose for renal or liver impairment, low serum albumin level, or bone marrow suppression; monitor for hypotension during infusion

Ifosfamide (Ifex)

Alkylating agent. Inhibits DNA and protein synthesis and therefore cell proliferation by causing DNA cross-linking and denaturation of double helix.

Dosing

Adult

1.8 g/m²/d IV for 5 d

Pediatric

1.6-2.4 g/m²/d IV for 5 d

Interactions

Phenobarbital, phenytoin, chloral hydrate, and other drugs that interfere with CYP activity may alter effects of ifosfamide; coadministration with warfarin may result in increased international normalized ratio (INR); may interfere with immune response to live virus vaccine (MMR) and reduce efficacy

Contraindications

Documented hypersensitivity; severe bone marrow depression; severe hemorrhagic cystitis

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

May cause hemorrhagic cystitis and severe myelosuppression; caution in renal function impairment or compromised bone-marrow reserve

Irinotecan (Camptosar, CPT-11)

Topoisomerase I inhibitor. Use in RMS currently investigational.

Dosing

Adult

150 mg/m² IV qwk

Pediatric

20 mg/m²/d IV for 5 d

Interactions

Concomitant administration with other antineoplastic agents may prolong neutropenia and thrombocytopenia and increase morbidity and/or mortality; coadministration with dexamethasone increases risk of lymphocytopenia

Contraindications

Documented hypersensitivity; severe diarrhea; febrile neutropenia; unresponsive or progressive adenocarcinoma; pregnancy

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Adverse effects include myelosuppression, alopecia, nausea, vomiting, and diarrhea; monitor bone marrow function

Uroprotective antidote

Mesna is a prophylactic detoxifying agent used to inhibit hemorrhagic cystitis caused by ifosfamide and cyclophosphamide. In the kidney, mesna disulfide is reduced to free mesna. Free mesna has thiol groups that react with acrolein, the ifosfamide and cyclophosphamide metabolite considered to be responsible for urotoxicity.

Mesna (Mesnex)

Inactivates acrolein and prevents urothelial toxicity without affecting cytostatic activity. Sulfhydryl compound that accumulates in urine and inactivates toxic byproducts of cyclophosphamide and ifosfamide.

Dosing

Adult

20% of ifosfamide dose IV (weight of solute per weight of solvent [w/w]); dosage depends on ifosfamide or cyclophosphamide; in clinical trials, 60-160% of antineoplastic agent used; may be administered as initial bolus followed by continuous or intermittent IV infusions before and after chemotherapy regimen

Pediatric

240-440 mg/m² PO/IV q3h before and after cyclophosphamide or ifosfamide dose

Interactions

May increase warfarin effect, adjust dose according to target INR

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Monitor morning urine for hematuria before ifosfamide or cyclophosphamide dose; common adverse effects include hypotension, headache, GI tract toxicity, and limb pain; do not use multidose vial for IV administration in neonates or infants (contains benzyl alcohol)

Colony-stimulating factors

These agents act as hematopoietic growth factors that stimulate the development of granulocytes. They are used to treat or prevent neutropenia when patients are receiving myelosuppressive cancer chemotherapy and to reduce the period of neutropenia associated with bone marrow transplantation. They are also used to mobilize autologous peripheral blood progenitor cells for bone marrow transplantation and in the management of chronic neutropenia. They shorten the time to neutrophilic recovery after chemotherapy.

Filgrastim (Neupogen)

Granulocyte colony-stimulating factor (G-CSF) that activates and stimulates production, maturation, migration, and cytotoxicity of neutrophils. Better tolerated than alternative GM-CSF.

Dosing

Adult

5-10 mcg/kg/d IV/SC

Pediatric

Administer as in adults

Interactions

Do not use 12-24 h before or 24 h after administering cytotoxic chemotherapy because increases sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

May cause bone pain or flulike symptoms

Follow-up

Further Inpatient Care

• Chemotherapy: Chemotherapy cycles are usually administered every 3 weeks (although vincristine is periodically given weekly) in patients with rhabdomyosarcoma (RMS), depending on recovery of the bone marrow. Patients receiving cycles that include cyclophosphamide, ifosfamide, and etoposide generally require inpatient admission for drug administration and monitoring.
• Fever and neutropenia: Admission is required to administer intravenous (IV) antibiotics and to monitor patients.
• Other reasons for inpatient care: Patients may require admission for a multitude of other medical problems during the chemotherapy phase of treatment, including varicella infection (to administer IV acyclovir and to monitor), mucositis (resulting from narcotics use), dehydration, meningitis, constipation, fungal pneumonia, and cystitis, among others.

Further Outpatient Care

• CBC count: Perform a CBC count twice each week in patients receiving therapy by using granulocyte-colony stimulating factor (G-CSF) so that G-CSF can be discontinued when the absolute neutrophil count has reached a predetermined level (usually 1 or 5 X 10⁹/L [1000 or 5000/µL]).
• Blood chemistry: Monitor blood chemistry results and liver function in patients receiving parenteral nutrition or in those who have a history of toxicity, especially if the patient continues to receive nephrotoxic or hepatotoxic antibiotics or other drugs.
• Chemotherapy: Depending on the protocol, some chemotherapy regimens (eg, vincristine, dactinomycin in particular) can be administered on an outpatient basis.
• Monitoring for recurrence: Continue to perform blood tests and radiographic scans on an outpatient basis, with the frequency decreasing over time. In general, patients should be examined every 3 months for the first year, every 6 months for the second and third years, and yearly thereafter.
• Long-term follow-up care: At 5 or longer after the end of therapy, patients are considered to be long-term survivors. Patients should be examined annually at a late-effects clinic and monitored with appropriate studies depending on the type of therapy they received. Visits may include hormonal, psychosocial, and neurologic evaluations, as well as follow-up examinations by the radiotherapist.

Inpatient & Outpatient Medications

• Trimethoprim-sulfamethoxazole: Prophylaxis against pneumocystic pneumonia should continue until 6 months after the end of chemotherapy.
• Fluconazole: Systemic fungal prophylaxis is not necessary.
• Clotrimazole: Prophylactic therapy for thrush may be discontinued after chemotherapy is completed.
• Chlorhexidine mouth rinse: Prophylaxis against gingivitis and other mouth infections may be discontinued after chemotherapy is completed.

Transfer

• Although major cancer therapy should take place at a center with pediatric oncologists, the child's referring pediatrician or general practitioner should continue to play an important role in the child's care throughout treatment.
• The referring physician can be critical in performing the first evaluation of an illness, particularly if the child lives far from an oncology center.

Deterrence/Prevention

• No preventive measures are known for childhood cancers.

Complications

The treatment of rhabdomyosarcoma results in a multitude of potential long-term adverse effects.¹⁹ The most common findings include the following:

• Cardiomyopathy
  • In patients who receive an anthracycline, cardiac function must be monitored to assess for the development of cardiomyopathy.
  • Cardiomyopathy may also from cyclophosphamide use.
• Pulmonary failure
• Metabolic derangements: Ifosfamide use, in particular, can lead to renal electrolyte wasting (Fanconi syndrome).
• Secondary malignant neoplasms
  • Secondary malignant neoplasms may arise as a result of radiotherapy and chemotherapy, particularly with alkylating agents.
  • Etoposide markedly increases the risk for acute myelogenous leukemia, particularly when regimens with frequent dosing schedules are used.
  • Radiation therapy increases the risk of second malignancies, including skin and bone tumors.

Patient Education

• Chemotherapy: Parents and patients (if appropriate) must undergo formal training to learn about the adverse effects of chemotherapy. They must know what is expected to happen as a result of the therapy and are encouraged to ask questions.
• Central venous catheters
  • When patients have central venous catheters that exit the skin (eg, Hickman or Broviac catheters), the parents or the patient must learn to properly care for the line. This care usually involves daily heparin flushes.
  • Patients and parents must understand the limitations on activities because of central venous catheters. For example, swimming is not permitted.
  • Patients with subcutaneous catheters (eg, Mediport catheters) do not need to perform daily care, but they should learn to apply a topical anesthetic (eg, EMLA cream, or lidocaine-prilocaine cream) at least 1 hour before an anticipated needle stick.

Miscellaneous

Medicolegal Pitfalls

• Although uncommon, legal issues associated with delayed diagnosis of rhabdomyosarcoma (RMS) are becoming more important, especially to primary care providers.
• Therefore, rhabdomyosarcoma must be considered in the differential diagnosis in any patient with symptoms suggestive of cancer or a palpable mass.

References

1. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. Jul 29 1999;341(5):342-52. [Medline].

2. Stout AP. Rhabdomyosarcoma of the skeletal muscles. Ann Surg. 1946;123:447-72.

3. Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol. Aug 1995;13(8):2123-39. [Medline].

4. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol. Nov-Dec 1997;19(6):483-91. [Medline].

5. Merlino G, Helman LJ. Rhabdomyosarcoma--working out the pathways. Oncogene. Sep 20 1999;18(38):5340-8. [Medline].

6. Punyko JA, Mertens AC, Baker KS, et al. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer. Apr 1 2005;103(7):1475-83. [Medline].

7. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. May 10 2008;26(14):2384-9. [Medline].

8. Mazzoleni S, Bisogno G, Garaventa A, et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer. Jul 1 2005;104(1):183-90. [Medline].

9. Gripp KW. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet. Aug 15 2005;137C(1):72-7. [Medline].

10. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol. Nov-Dec 1998;1(6):550-61. [Medline].

11. Wolden SL, Wexler LH, Kraus DH, et al. Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. Apr 1 2005;61(5):1432-8. [Medline].

12. Yock T, Schneider R, Friedmann A, et al. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys. Nov 15 2005;63(4):1161-8. [Medline].

13. Currier MA, Adams LC, Mahller YY, et al. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther. Apr 2005;12(4):407-16. [Medline].

14. Modak S, Guo HF, Humm JL, et al. Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother Radiopharm. Oct 2005;20(5):534-46. [Medline].

15. Bersani F, Taulli R, Accornero P, et al. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur J Cancer. Apr 2008;44(6):876-84. [Medline].

16. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor i receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. Oct 1 2008;68(19):8039-48. [Medline].

17. Klingebiel T, Boos J, Beske F, et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer. Apr 2008;50(4):739-45. [Medline].

18. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol. Feb 1 2007;25(4):362-9. [Medline].

19. Punyko JA, Mertens AC, Gurney JG, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. Pediatr Blood Cancer. Jun 15 2005;44(7):643-53. [Medline].

20. Pappo AS, Shapiro DN, Crist WM. Rhabdomyosarcoma. Biology and treatment. Pediatr Clin North Am. Aug 1997;44(4):953-72. [Medline].

Keywords

rhabdomyosarcoma, RMS, alveolar rhabdomyosarcoma, botryoid rhabdomyosarcoma, embryonal rhabdomyosarcoma, spindle cell rhabdomyosarcoma, pleomorphic rhabdomyosarcoma, soft tissue sarcoma, rhabdomyoblasts, pediatric sarcoma, sarcoma, respiratory difficulty, lung nodules, pleural effusion, anemia, thrombocytopenia, neutropenia, menorrhagia, metrorrhagia, neurofibromatosis, Li-Fraumeni syndrome, Rubinstein-Taybi syndrome, Gorlin basal cell nevus syndrome, Beckwith-Wiedemann syndrome, Costello syndrome, Arnold-Chiari malformation

Contributor Information and Disclosures

Author

Timothy P Cripe, MD, PhD, Professor of Pediatric Hematology/Oncology, University of Cincinnati; Director, Translational Research Trials Office, Department of Pediatrics, Cincinnati Children's Hospital Medical Center
Timothy P Cripe, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Medical Editor

Samuel Gross, MD, Professor Emeritus, Department of Pediatrics, University of Florida, Clinical Professor, Department of Pediatrics, UNC, Adjunct Professor, Department of Pediatrics, Duke University
Samuel Gross, MD is a member of the following medical societies: American Association for Cancer Research, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Steven K Bergstrom, MD, Assistant to the Chairman, Department of Pediatrics, Division of Hematology-Oncology, Kaiser Permanente Medical Center of Oakland
Steven K Bergstrom, MD is a member of the following medical societies: Alpha Omega Alpha, American Society of Clinical Oncology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Children's Oncology Group, and International Society for Experimental Hematology
Disclosure: Nothing to disclose.

CME Editor

Paul D Petry, DO, FACOP, FAAP, Consulting Staff, Freeman Pediatric Care, Freeman Health System
Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association
Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA, Executive Director, Center for Cancer and Blood Disorders, Children's National Medical Center; Professor of Medicine, Oncology, and Pediatrics, Georgetown University
Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American Association for Cancer Research, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research
Disclosure: Nothing to disclose.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)